Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Trial to Evaluate the Pharmacokinetics of MK-3402 Following Administration of a Single IV Dose to Participants With Mild, Moderate, and Severe Renal Impairment and End-Stage Renal Disease

NCT04678505 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT04678505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Trial to Evaluate the Pharmacokinetics of MK-3402 Following Administration of a Single IV Dose to Participants With Mild, Moderate, and Severe Renal Impairment and End-Stage Renal Disease
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Terminated
Start date
February 10, 2021
Completion date
April 27, 2021
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment